Answers are grounded in this paper and cite their sources.
Background Mucopolysaccharidoses (MPS) IVA and VI are rare, progressive disorders for which enzyme replacement therapy (ERT) and regular clinical monitoring are recommended to optimize outcomes. However, in public health systems such as Brazil's Unified Health System (SUS), the real-world implementation of therapeutic guidelines remains challenging and insufficiently documented. Objective This study aims to analyze the challenges and opportunities in implementing therapeutic guidelines for Mucopolysaccharidosis (MPS) IVA and VI in Brazil, focusing on clinical monitoring and treatment adherence within public healthcare institutions. Methods This Phase 4, non-interventional, multicenter prospective cohort study was conducted across nine Brazilian institutions. Medical chart data covering up to 3 years were collected from participants receiving enzyme replacement therapy (ERT) with elosulfase alfa or galsulfase through the Unified Health System (SUS). Variables included demographics, treatment exposure, adherence, the number and reasons for not performing clinical and functional assessments (urinary glycosaminoglycans, pulmonary function tests, 6-minute walk test, and quality of life scales). Adherence was calculated as the proportion of infusions received vs. those expected. Results Twenty participants were enrolled (11 MPS IVA; nine MPS VI), with median ages of 9.0 and 3.0 years and mean ERT exposure of 1.3 and 1.6 years, respectively. Clinical and functional assessments were largely incomplete at baseline and remained inconsistent throughout follow-up. Although exam frequency increased, particularly in MPS IVA, monitoring remained irregular in both cohorts. The main reasons for missed assessments were lack of physician request, equipment unavailability, logistical barriers, and patient limitations; several tests were also considered not applicable due to age or clinical condition. Overall, operational constraints are limited to standardized clinical and functional monitoring. Conclusion MPS care guidelines are formally established in Brazil, but their full implementation is limited by inconsistent clinical monitoring due to operational constraints. Reducing logistical barriers and standardizing follow-up protocols may enhance patient outcomes and support long-term access to high-cost therapies in the public health system.
No takes yet. Share an insight, caveat, or question.
Siqueira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: